Several new anticoagulants have entered the clinical arena or are under clinical
development. These drugs include indirect (fondaparinux) and direct oral factor Xa inhibitors …

Maintaining normal hemostasis relies on a regulated system of procoagulant and
anticoagulant pathways, and disruption of these processes leads to the loss of hemostatic …

Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against
human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII …

The development of alloantibodies neutralising therapeutically administered factor (F) VIII/IX
(inhibitors) is currently the most severe complication of the treatment of haemophilia. When …

Trauma-induced coagulopathy (TIC) is a recently described condition which traditionally has
been diagnosed by the common coagulation tests (CCTs) such as prothrombin …

With advances in care, increasing numbers of people with hemophilia (PWH) achieve near-
normal life expectancies and present with typical age-related cardiovascular conditions …

Background The management of hemophilia A (HA) patients with inhibitors on bypassing
therapy remains challenging. In particular, the monitoring of treatment is restricted by the …

Thrombin plays an essential role in achieving and maintaining effective hemostasis and
stable clot formation. In people with hemophilia, deficiency of procoagulant factor (F) VIII or …

Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran)
and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical …

The management of patients with congenital hemophilia who develop alloantibodies that
neutralize coagulation factor activity is the most important challenge for hemophilia care …